Hospital

The study included the BNT162b2 and CoronaVac vaccines, which are the only COVID-19 vaccines authorized for emergency use in Hong Kong.

Investigators also noted that Black, Hispanic, and Asian individuals were less likely than white individuals to undergo timely angiography and had minimal changes overtime.

More than three-quarters of deaths averted were attributed to the direct protection against severe symptoms provided by vaccination, leading to lower mortality rates.

Throughout the world, patients and health care professionals alike have become better acquainted with digital tools when face-to-face interactions became increasingly problematic.

As part of the submission, the companies have also requested priority review with the FDA for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer.

Infection in pregnancy increases the risk for preterm delivery and other adverse pregnancy outcomes, including stillbirth.

Clorazepate dipotassium tablets are for the management of anxiety disorders or for the short-term relief of symptoms.

At 1 month, a 50-µg booster dose of mRNA-1273.214 had a potent neutralizing antibody response against the Omicron variants in all individuals, regardless of prior infection.

The researchers noted that new therapies have faced challenges because of this knowledge gap in CHD.

As we mark the second anniversary of Bostock v. Clayton County this month, let’s remember to treat each other with dignity, empathy, and respect, while we work together for a safer and more tolerant workplace.

Lenvima (lenvatinib) is approved for the treatment of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.

Clinical evaluation dictates the need for preventive therapy and advice on exercising and participation in competitive sports, according to the European Society of Cardiology.

Lisocabtagene maraleucel (liso-cel, Breyanzi; Bristol Myers Squibb) approved for the second-line treatment of patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, and follicular lymphoma grade 3B.

Analysis results expand understanding of the impact of the company’s medicines in early stages with the goal or providing patients with durable and robust outcomes from their first treatment.

This is the first RSV vaccination candidate to show clinically meaningful and statistically significant efficacy in adults aged 60 years and older.

Breast cancer screening guidelines using mammography vary among guiding bodies, including the American Cancer Society and the American Academy of Family Physicians.

Amy Cadwallader, PhD, director of Regulatory and Public Policy Development at US Pharmacopeia (USP), discusses how medicine quality and the medicines supply chain can affect antimicrobial resistance (AMR).

Abemaciclib (Verzenio; Eli Lilly and Company) is an FDA-approved kinase inhibitor being investigated for new indications in individuals with hormone-sensitive prostate cancer and castration-resistant prostate cancer.

Combination therapy with both nivolumab and relatlimab leads to increased T-cell activation compared with monotherapy with either agent alone.

Andrea Iannucci, PharmD, BCOP, member of the Board of Directors of the Hematology/Oncology Pharmacy Association (HOPA), discusses how HOPA works within and its impact on hematology/oncology pharmacy practice management.

The impact of the pandemic on the mental health of health care workers, including pharmacists and pharmacy staff, has been well documented.

Capecitabine (Xeloda) is indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.

Treatment identifies patients with ROS1 fusion-positive non-small cell lung cancer or those with NTRK fusion-positive solid tumors for whom treatment with Rozlytrek may be appropriate.

Analysis shows that individuals who received treatment within 3 days of symptom onset with tixagevimab and cilgavimab reduced their risk by 88% compared with the placebo.

In clinical trials, dabrafenib and trametinib showed meaningful efficacy in multiple BRAF-positive tumor types, including in patients with rare cancers who have no other treatment options available.

The survey results come as the ACIP evaluates data to provide guidance for flu vaccines in older adults.

Jardiance shows reduction of 50% compared with dipeptidyl peptidase-4 inhibitors and 30% compared with glucagon-like peptide 1 receptor agonists.

Data show significantly higher geometric mean titer ratios, meeting prespecified endpoints for superiority against the variant.